Today's formalised 65% acquisition of Telemedcare can only bring...

Today's formalised 65% acquisition of Telemedcare can only bring long term wealth to Stirling. Investors with a short-term mind set would have got out today. The figures in Quarterly report would have not helped calm their anxiety IMO. Until overall sale figures improve (which we should know by December), we will not see a sustained improvement in the SP IMO. However, any surprise announcements with Immunoxel, Animate, pharma plant etc may lead to another jump.

Questioning why STI had to go into a trading halt for this particular announcement should be self-evident IMO.


For those who see long term potential, here is an article highlighting the potential uptake of Telehealth in the Asian market. Telemedcare gets a mention.

http://www.asianhhm.com/information_technology/telehealth_asia_communities.htm


A key to manage the rising demand of aged care is to empower patients. As Professor Branko Celler, CEO of Australia's TeleMedCare explains, the empowerment of patients with the tools and the knowledge to self-manage a long-term condition, the facilitation of an all-population approach to improve healthcare outcomes at a distance by integrating social care, telecare and telehealth services throughout the primary care sector.�

On the Immunoxel/vaccine issue.

It has been proposed that immunoxel has the potential to be administered as an adjuvant with pre-existing HIV vaccines (the hypothesis been that Immunoxel may enhance the recipient's immune response to a supplied antigen and in doing so potentiates specific immune responses towards the vaccine peptide). Pre-existing human adjuvants including MF59, ISCOMS, QS21, AS02, and AS04 have substantially higher local reactogenicity and systemic toxicity than alum (the stock standard). Read:
http://biopharminternational.findpharma.com/biopharm/article/articleDetail.jsp?id=444996&sk=&date=&pageID=3

If Immunoxel performs better, this would be a big thing.


It is all of course a separate issue to Immunoxel improving the outcome of HIV, TB and influenza infections.